Open AccessMulticenter randomized study on Me-CCNU, 5-FU and ADMvsACNU, 5-FU and ADM for treatment of advanced gastric cancer
Author(s) -
Shu–Dong Xiao,
Dehua Li,
Zhang De-zhong,
Mou-Ji Shen,
Xiaoting Zhu,
Guifen He,
Tong Zhao,
Leping Li,
Xing-Cun Deng,
Min Wang,
Xiuling Wang,
Qiang Chen,
Yongping Zhang,
Cui-Ling Yao,
Junzhe Bao,
Tong Guo-wei,
Liang-Fa Zhu,
Hao Jiang,
Minoru Kurihara
Publication year - 1997
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v3.i4.238
Subject(s) - medicine , quality of life (healthcare) , regimen , nitrosourea , randomized controlled trial , group b , gastroenterology , adverse effect , cancer , chemotherapy , oncology , nursing
To compare the efficacy of a combined chemotherapy regimen of 5-fluouracil (5-FU) and adriamycin (ADM) with nimustine hydrochloride (ACNU; brand name Nidran), a new nitrosourea agent, or with methyl-CCNU for advanced gastric cancer.